Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.

ARS Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SAN DIEGO, OCT. 08, 2025 (GLOBE NEWSWIRE) -- ARS PHARMACEUTICALS, INC. (NASDAQ: SPRY), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEDICATED TO EMPOWERING AT-RISK PATIENTS AND THEIR CAREGIVERS TO BETTER PROTECT PATIENTS FROM ALLERGIC REACTIONS THAT COULD LEAD TO ANAPHYLAXIS, TODAY ANNOUNCED THE OPPOSITION DIVISION OF THE EUROPEAN PATENT OFFICE (THE EPO) UPHELD THE VALIDITY OF ALL CLAIMS IN EP 3678649, WHICH IS A PATENT VALIDATED IN OVER 30 EUROPEAN COUNTRIES DIRECTED TO NASAL SPRAY EPINEPHRINE FORMULATIONS INCLUDING ALKYL-GLYCOSIDE, SUCH AS INTRAVAIL, AND USES THEREOF. ARS PHARMA'S ISSUED GLOBAL INTELLECTUAL PROPERTY PORTFOLIO RELATED TO NEFFY PROVIDES COVERAGE UNTIL AT LEAST 2039.

ARS PHARMACEUTICALS RECEIVES FAVORABLE DECISION FROM EUROPEAN PATENT OFFICE ON PATENT RELATED TO NEFFY (EPINEPHRINE NASAL SPRAY)

INITIAL $100 MILLION TERM LOAN TO PROPEL MARKET SHARE GROWTH IN THE U.S. SAN DIEGO, SEPT. 29, 2025 (GLOBE NEWSWIRE) -- ARS PHARMACEUTICALS, INC. (NASDAQ: SPRY), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEDICATED TO EMPOWERING AT-RISK PATIENTS AND THEIR CAREGIVERS TO BETTER PROTECT PATIENTS FROM ALLERGIC REACTIONS THAT COULD LEAD TO ANAPHYLAXIS, TODAY ANNOUNCED IT HAS ENTERED INTO A SENIOR SECURED TERM LOAN FACILITY OF UP TO $250 MILLION WITH AN AFFILIATE OF RA CAPITAL MANAGEMENT (RA CAPITAL), THE COMPANY'S LARGEST SHAREHOLDER, AND AN AFFILIATE OF OMERS LIFE SCIENCES AS LENDERS.

ARS PHARMACEUTICALS SECURES UP TO $250 MILLION LOAN FACILITY WITH RA CAPITAL MANAGEMENT AND OMERS LIFE SCIENCES TO ACCELERATE U.S. COMMERCIALIZATION OF NEFFY

 ACCOMPLISHED BIOPHARMA EXECUTIVE AND ENTREPRENEUR BRINGS A 25-YEAR TRACK RECORD OF UPSCALING VALUABLE COMPANIES AND REALIZING THE POTENTIAL OF THEIR INNOVATIONS  SAN DIEGO, SEPT. 17, 2025 (GLOBE NEWSWIRE) -- ADARX PHARMACEUTICALS, INC. (ADARX), A LATE-STAGE CLINICAL BIOTECHNOLOGY COMPANY DEVELOPING NEXT-GENERATION RNA THERAPEUTICS, TODAY ANNOUNCED THE APPOINTMENT OF LAURA SHAWVER, PH.D.

ADARX PHARMACEUTICALS APPOINTS INDUSTRY VETERAN, LAURA SHAWVER, PH.D., AS BOARD CHAIR

FINDINGS ACCEPTED FOR PUBLICATION IN THE OFFICIAL JOURNAL OF THE AMERICAN COLLEGE OF ALLERGY, ASTHMA AND IMMUNOLOGY ABOUT 9 OUT OF EVERY 10 PATIENTS EXPERIENCING ANAPHYLAXIS WERE EFFECTIVELY TREATED WITH A SINGLE DOSE OF NEFFY RESULTS SUGGEST REAL-WORLD EFFECTIVENESS OF NEFFY IS CONSISTENT WITH THAT HISTORICALLY REPORTED FOR EPINEPHRINE INJECTION SAN DIEGO, SEPT. 08, 2025 (GLOBE NEWSWIRE) -- ARS PHARMACEUTICALS, INC. (NASDAQ: SPRY), A COMMERCIAL STAGE BIOPHARMACEUTICAL COMPANY DEDICATED TO EMPOWERING AT-RISK PATIENTS AND THEIR CAREGIVERS TO BETTER PROTECT PATIENTS FROM ALLERGIC REACTIONS THAT COULD LEAD TO ANAPHYLAXIS, TODAY SHARES REAL-WORLD EVIDENCE EVALUATING THE CLINICAL PERFORMANCE OF NEFFY  (EPINEPHRINE NASAL SPRAY) IN PATIENTS EXPERIENCING ANAPHYLAXIS SYMPTOMS DURING ORAL FOOD CHALLENGE AND ALLERGEN IMMUNOTHERAPY.

REAL-WORLD EVIDENCE SUPPORTS CLINICAL EFFECTIVENESS OF NEFFY (EPINEPHRINE NASAL SPRAY) IN PATIENTS EXPERIENCING ANAPHYLAXIS

SAN DIEGO, AUG. 28, 2025 (GLOBE NEWSWIRE) -- ARS PHARMACEUTICALS, INC.(NASDAQ: SPRY), A BIOPHARMACEUTICAL COMPANY DEDICATED TO EMPOWERING AT-RISK PATIENTS AND THEIR CAREGIVERS TO BETTER PROTECT THEMSELVES FROM ALLERGIC REACTIONS THAT COULD LEAD TO ANAPHYLAXIS, TODAY ANNOUNCED THAT RICHARD LOWENTHAL, CO-FOUNDER, PRESIDENT AND CEO ANDERIC KARAS, CHIEF COMMERCIAL OFFICER WILL PARTICIPATE IN PRESENTATIONS AT THE CANTOR GLOBAL HEALTHCARE CONFERENCE AND THE STIFEL IMMUNOLOGY AND INFLAMMATION SUMMIT IN SEPTEMBER. DETAILS OUTLINED BELOW.

ARS PHARMACEUTICALS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

$15.7 MILLION IN REVENUE, INCLUDING $12.8 MILLION IN NEFFY U.S. NET PRODUCT REVENUE IN SECOND QUARTER OF 2025

ARS PHARMACEUTICALS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND HIGHLIGHTS ACCELERATING GROWTH FOR NEFFY (EPINEPHRINE NASAL SPRAY)

SAN DIEGO, AUG. 04, 2025 (GLOBE NEWSWIRE) -- ARS PHARMACEUTICALS, INC. (NASDAQ: SPRY), A BIOPHARMACEUTICAL COMPANY DEDICATED TO EMPOWERING AT-RISK PATIENTS AND THEIR CAREGIVERS TO BETTER PROTECT PATIENTS FROM ALLERGIC REACTIONS THAT COULD LEAD TO ANAPHYLAXIS, TODAY ANNOUNCED THE COMPANY WILL HOST A CONFERENCE CALL AND WEBCAST ON WEDNESDAY, AUGUST 13, 2025, AT 5:30 A.M. PT / 8:30 A.M.

ARS PHARMACEUTICALS ANNOUNCES CONFERENCE CALL AND WEBCAST FOR ITS SECOND QUARTER 2025 FINANCIAL RESULTS

EUR NEFFY ( NEFFY  IN THE U.S.) OFFERS A NEW DELIVERY METHOD FOR ADRENALINE IN THE U.K. FOR ADULTS AND CHILDREN ( > 30 KG) LIVING WITH SEVERE ALLERGIC REACTIONS

EURNEFFY (ADRENALINE NASAL SPRAY) APPROVED IN THE U.K. AS THE FIRST AND ONLY NEEDLE-FREE EMERGENCY TREATMENT OF ALLERGIC REACTIONS (ANAPHYLAXIS)

SAN DIEGO, MAY 27, 2025 (GLOBE NEWSWIRE) -- ARS PHARMACEUTICALS, INC.(NASDAQ: SPRY), A BIOPHARMACEUTICAL COMPANY DEDICATED TO EMPOWERING AT-RISK PATIENTS AND THEIR CAREGIVERS TO BETTER PROTECT THEMSELVES FROM ALLERGIC REACTIONS THAT COULD LEAD TO ANAPHYLAXIS, TODAY ANNOUNCED THAT RICHARD LOWENTHAL, CO-FOUNDER, PRESIDENT AND CEO ANDERIC KARAS, CHIEF COMMERCIAL OFFICER, WILL PARTICIPATE IN PRESENTATIONS AT THE WILLIAM BLAIR 45TH ANNUAL GROWTH STOCK CONFERENCE AND 2025 JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN JUNE.

$7.8 MILLION IN TOTAL NEFFY U.S. NET PRODUCT REVENUE IN FIRST QUARTER OF 2025 NEFFY 1 MG AVAILABLE NATIONWIDE FOR CHILDREN AGED FOUR AND OLDER AND CO-PROMOTION AGREEMENT WITH ALK-ABELL INC. INCREASES NEFFY PROMOTIONAL REACH TO NEARLY 20,000 HEALTHCARE PROVIDERS, INCLUDING KEY PEDIATRICIANS MORE THAN 5,000 PHYSICIANS HAVE PRESCRIBED NEFFY TO DATE, REINFORCING THE DEMAND FOR A SAFE, EFFECTIVE, NEEDLE-FREE TREATMENT FOR SEVERE ALLERGIC REACTIONS INCLUDING ANAPHYLAXIS CONFERENCE CALL TO BE HELD TODAY, MAY 14, 2025, AT 5:30 A.M. PT / 8:30 A.M.

ARS PHARMACEUTICALS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND HIGHLIGHTS PROGRESS IN U.S. COMMERCIAL LAUNCH OF NEFFY (EPINEPHRINE NASAL SPRAY)

THE AVAILABILITY OF NEFFY 1 MG EXTENDS PROTECTION TO YOUNGER, SCHOOL-AGED CHILDRENWHO MAKE UP NEARLY 23% OF PEOPLE NEEDING EPINEPHRINE VISIT NEFFY.COM FOR SAVINGS AND SUPPORT PROGRAMS AND PAY AS LITTLE AS $25 (IF ELIGIBLE) IN PREPARATION FOR SUMMER TRAVEL AND BACK-TO-SCHOOL SAN DIEGO, MAY 07, 2025 (GLOBE NEWSWIRE) -- ARS PHARMACEUTICALS, INC. (NASDAQ: SPRY), A BIOPHARMACEUTICAL COMPANY DEDICATED TO EMPOWERING AT-RISK PATIENTS AND THEIR CAREGIVERS TO BETTER PROTECT PATIENTS FROM ALLERGIC REACTIONS THAT COULD LEAD TO ANAPHYLAXIS, ANNOUNCED NEFFY  (EPINEPHRINE NASAL SPRAY) 1 MG IS NOW AVAILABLE TO PATIENTS AND CAREGIVERS BY PRESCRIPTION ACROSS THEU.S. IN MARCH 2025, THE U.S. FOOD AND DRUG ADMINISTRATION APPROVED NEFFY FOR THE TREATMENT OF TYPE I ALLERGIC REACTIONS, INCLUDING ANAPHYLAXIS, IN CHILDREN WHO ARE AGED FOUR YEARS AND OLDER AND WEIGH 15 TO < 30 KILOGRAMS (33 TO < 66 LB.). MANY CHILDREN FEAR NEEDLES, WHICH CAN LEAD PARENTS TO DELAY ADMINISTERING NEEDLE-BASED EPINEPHRINE TREATMENTS.

ARS PHARMACEUTICALS' NEFFY (EPINEPHRINE NASAL SPRAY) 1 MG IS NOW AVAILABLE IN THE UNITED STATES FOR TYPE I ALLERGIC REACTIONS, INCLUDING ANAPHYLAXIS, IN PEDIATRIC PATIENTS WEIGHING 15 TO < 30 KILOGRAMS

ARS Pharmaceuticals, Inc.

SPRY

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ARS Pharmaceuticals, Inc.

SPRY.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

SPRY